首页> 外文期刊>Clinical, Cosmetic and Investigational Dermatology >Paraneoplastic pemphigus: a short review
【24h】

Paraneoplastic pemphigus: a short review

机译:副肿瘤性天疱疮:简短回顾

获取原文
       

摘要

Paraneoplastic pemphigus (PNP) is a fatal autoimmune blistering disease associated with an underlying malignancy. It is a newly recognized blistering disease, which was first recognized in 1990 by Dr Anhalt who described an atypical pemphigus with associated neoplasia. In 2001, Nguyen proposed the term paraneoplastic autoimmune multiorgan syndrome because of the recognition that the condition affects multiple organ systems. PNP presents most frequently between 45 and 70 years old, but it also occurs in children and adolescents. A wide variety of lesions (florid oral mucosal lesions, a generalized polymorphous cutaneous eruption, and pulmonary involvement) may occur in patients with PNP. The earliest and most consistent finding is severe stomatitis. There is a spectrum of at least five clinical variants with different morphology. Similarly, the histological findings are very variable. Investigations to diagnose PNP should include checking for systemic complications (to identify tumor), skin biopsies (for histopathological and immunofluorescence studies), and serum immunological studies. PNP is characterized by the presence of autoantibodies against antigens such as desmoplakin I (250 kD), bullous pemphigoid aniygen I (230 kD), desmoplakin II (210 kD), envoplakin (210 kD), periplakin (190 kD), plectin (500 kD), and a 170 kD protein. Unlike other forms of pemphigus, PNP can affect other types of epithelia, such as gastrointestinal and respiratory tract. Treatment of PNP is difficult, and the best outcomes have been reported with benign neoplasms that have been surgically excised. The first-line treatment is high-dose corticosteroids with the addition of steroid-sparing agents. Treatment failures are often managed with rituximab with or without concomitant intravenous immunoglobulin. In general, the prognosis is poor, not only because of eventual progression of malignant tumors but also because treatment with aggressive immunosuppression therapy often results in infectious complications, which is unfortunately at this time the most common cause of death in PNP.
机译:副肿瘤性天疱疮(PNP)是一种致命的自身免疫性水疱性疾病,与潜在的恶性肿瘤相关。它是一种新发现的水疱病,1990年由Anhalt博士首次发现,他描述了一种非典型的天疱疮并伴有肿瘤。在2001年,Nguyen提出了术语副肿瘤性自身免疫多器官综合征,因为人们认识到该病会影响多器官系统。 PNP最常出现在45至70岁之间,但它也发生在儿童和青少年中。 PNP患者可能会发生各种各样的病变(口腔粘膜病变,广泛性多态性皮疹和肺部受累)。最早且最一致的发现是严重的口腔炎。至少有五种具有不同形态的临床变体。同样,组织学发现也有很大差异。诊断PNP的检查应包括检查全身并发症(以识别肿瘤),皮肤活检(用于组织病理学和免疫荧光研究)和血清免疫学研究。 PNP的特征是存在针对抗原的自身抗体,例如抗桥蛋白I(250 kD),大疱性类天疱疮性苯胺基因I(230 kD),除桥蛋白II(210 kD),肠粘膜蛋白(210 kD),周膜蛋白(190 kD),凝集素(500) kD)和170 kD蛋白。与其他形式的天疱疮不同,PNP可以影响其他类型的上皮细胞,例如胃肠道和呼吸道。 PNP的治疗很困难,据报道,手术切除的良性肿瘤效果最好。一线治疗是大剂量皮质类固醇与类固醇保护剂的添加。治疗失败通常用利妥昔单抗治疗,伴或不伴静脉注射免疫球蛋白治疗。通常,预后很差,这不仅是由于恶性肿瘤的最终进展,还因为积极的免疫抑制疗法通常会导致感染性并发症,不幸的是,这是目前PNP死亡的最常见原因。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号